Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Horizon Pharma

The FTC is preparing to seek an injunction in federal court that would prevent the deal from closing.

FTC Poised to Block Amgen's $27.8 Billion Deal for Horizon Therapeutics

Shares of Horizon Therapeutics tumbled on Tuesday following a report that the Federal Trade Commission (FTC) is preparing to block its $27.8 billion sale to Amgen. Per a Bloomberg report citing an unnamed source familiar with the matter, the FTC could file a lawsuit to block the acquisition as soon as Tuesday.

FTC to challenge Amgen's $27.8B acquisition of Horizon Therapeutics: report

Seagen

Prometheus Biosciences

Reports the FTC could block Amgen's takeover of Horizon reverberated across biotech stocks on Tuesday, with HZNP stock's crash leading the way. The post Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover appeared first on Investor's Business Daily.

Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover

The deal is bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.

Horizon Therapeutics stock plunges on report FTC is preparing to block Amgen deal

Amgen reached an agreement to buy Horizon for $27.8 billion in December last year, and at the time said it expected the deal to be completed in the first half of 2023.

Horizon Therapeutics Stock Plunges on Reports FTC Will Sue to Block Amgen Deal

Apple

Arbor Realty Trust

Archer-Daniels-Midland Company

Aflac

Assured Guaranty

Apartment Income REIT Corp

Ameriprise Financial

Artesian Resources

Ashland Global Hlds

Atmos Energy

Atlantic Union Bankshares Corp

Armstrong World Industries

American States Water

Black Hills

Brown & Brown

BWX Technologies

Cardinal Health

Caterpillar

Cabot

Cogent Communications Holdings

Cognex

Cummins

Costco

Carlisle Companies

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.

Dividend Champion, Contender, And Challenger Highlights: Week Of May 14

Amgen Inc. (NASDAQ:AMGN ) BofA Securities 2023 Health Care Conference May 9, 2023 11:00 AM ET Company Participants Peter Griffith - CFO Dave Reese - EVP, R&D Conference Call Participants Dan Lundquist - Ban of America Dan Lundquist Hello. Good morning, everybody.

Amgen Inc. (AMGN) Presents at BofA Securities 2023 Health Care Conference (Transcript)

NEW YORK , May 12, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/amgen-inc-lawsuit-submission-form/?id=39264&from=4 This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.

AMGN SHAREHOLDER ALERT: Jakubowitz Law Reminds Amgen Shareholders of a Lead Plaintiff Deadline of May 12, 2023

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming May 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN) common stock between July 29, 2020 and April 27, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On August 3, 2021, Amgen released its second quarter 2021 financial resul.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)

NEW YORK , May 11, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected by alleged securities fraud.

AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , May 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN

Boeing

Salesforce

Cisco Systems

Chevron

Disney

Dow Inc

Goldman Sachs

Intel

Johnson & Johnson

JPMorgan Chase & Co

UnitedHealth Group

Verizon

Walgreens

"The Dow adds a stock if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.” - Dow Jones & Co. The highest-yield 10 stocks are May's Dogs of the Dow: JNJ, GS, CSCO, AMGN, CVX, DOW, IBM, MMM, WBA, and VZ, averaged a 4.65% annual yield.

May Dogs Of The Dow: Buy 2, Watch 4

RADNOR, Pa. , May 10, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN).

AMGN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. (AMGN) Shareholders of Securities Fraud Class Action Lawsuit

NEW YORK , May 10, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Amgen Inc.. Shareholders who purchased shares of AMGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 - (NASDAQ: AMGN)

TScan Therapeutics

Shares of TScan Therapeutics Inc. TCRX powered up 43.1% in premarket trading Tuesday, after the biopharmaceutical company announced a collaboration with Amgen Inc. AMGN to treat Crohn's disease that could be worth more than $500 million to TScan. Amgen shares slipped 0.1% ahead of the open.

TScan Therapeutics stock soars after Amgen collaboration on Crohn's disease treatment that could bring in more than $500 million

Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass.

AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE

Applied Materials

Danaher

Home Depot

Jacobs Solutions Inc

Lowe's

Lam Research

NIKE

Paychex

Progressive

Raymond James

Stryker

Warren Buffett held court again at Berkshire Hathaway's shareholder meeting. But his company could learn from some other S&P 500 companies.

16 Stocks Run Circles Around Warren Buffett Over The Long Haul

NEW YORK , May 9, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws. This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.Lead Plaintiff Deadline: May 12, 2023 No obligation or cost to you.

AMGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders

NEW YORK , May 8, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the "Class Period"), of the important May 12, 2023 lead plaintiff deadline. SO WHAT: If you purchased Amgen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

AMGN FINAL DEADLINE MAY 12: ROSEN, A TOP RANKED LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - AMGN

Real World Evidence Study Showed use of Prolia Reduced Fracture Risk in Postmenopausal Women With Osteoporosis Versus Alendronate Treatment Longer Duration of Treatment With Prolia Was Associated With Greater Improvements in Fracture Risk Reduction Data is From Real-World Study with Nearly Half a Million Patients Comparing Prolia to Alendronate THOUSAND OAKS, Calif. , May 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia® (denosumab) injection reduced fracture risk in patients versus oral alendronate, a frequently prescribed bisphosphonate treatment.

NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE

BENSALEM, Pa. , May 8, 2023 /PRNewswire/ -- Law Offices of Howard G.

AMGN Investors Have Opportunity to Lead Amgen Inc. Securities Fraud Lawsuit

Did you lose money on investments in Amgen Inc.? If so, please visit Amgen Inc. Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen Inc. (NASDAQ: AMGN)

NEW YORK , May 8, 2023 /PRNewswire/ -- Attention Amgen Inc. ("Amgen") (NASDAQ: AMGN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Amgen Investors of a Lead Plaintiff Deadline of May 12, 2023

News for Amgen Stock (AMGN)